Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPOCA
NCT06930885Phase 3Recruiting
- Sponsor
- HCor
- Start
- Jun 2025
- Primary completion
- May 2031
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of aspirin + atorvastatin + hydrochlorothiazide + enalapril, colchicine in atherosclerotic cardiovascular disease (ASCVD), sponsored by HCor. Started Jun 2025; status: recruiting.
02
Drugs
aspirin + atorvastatin + hydrochlorothiazide + enalaprilcolchicine
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT06930885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06930885.